Temporal Trends of Digoxin Use in Patients Hospitalized With Heart Failure: Analysis From the American Heart Association Get With The Guidelines-Heart Failure Registry

详细信息    查看全文

• 作者：Nish Patel ; MD^a ; ^c ; Christine Ju ; MS^b ; Conrad Macon ; MD^a ; Udho Thadani ; MD^c ; Phillip J. Schulte ; PhD^b ; Adrian F. Hernandez ; MD^b ; Deepak L. Bhatt ; MD ; MPH^d ; Javed Butler ; MD ; MPH ; MBA^e ; Clyde W. Yancy ; MD^f ; Gregg C. Fonarow ; MD^g ; ^{gfonarow@mednet.ucla.edu" class="auth_mail" title="E-mail the corresponding author}
• 关键词：digoxin ; GWTG-HF ; heart failure ; trends
• 刊名：JACC: Heart Failure
• 出版年：2016
• 出版时间：May 2016
• 年：2016
• 卷：4
• 期：5
• 页码：348-356
• 全文大小：744 K

文摘

The aim of this study was to assess temporal trends and factors associated with digoxin use at discharge among patients admitted with heart failure (HF).

Background

Digoxin has class IIa recommendations for treating HF with reduced ejection fraction (HFrEF) in the United States. Digoxin use, temporal trends, and clinical characteristics of HF patients in current clinical practice in the United States have not been well studied.

Methods

An observational analysis of 255,901 patients hospitalized with HF (117,761 with HFrEF and 138,140 with preserved EF [HFpEF]) from 398 hospitals participating in the Get With The Guidelines–HF registry between January 2005 and June 2014 was conducted to assess the temporal trends and factors associated with digoxin use.

Results

Among 117,761 HFrEF patients, only 19.7% received digoxin at discharge. Digoxin prescriptions decreased from 33.1% in 2005 to 10.7% in 2014 (p_trend < 0.0001). Factors associated with digoxin use in HFrEF included atrial fibrillation (AF) (odds ratio [OR]: 2.14; 95% confidence intervals [CI]: 2.02 to 2.28), history of implantable cardioverter defibrillator use (OR: 1.39; 95% CI: 1.32 to 1.46), chronic obstructive pulmonary disease (OR: 1.13, 95% CI: 1.08 to 1.18), diabetes mellitus (OR: 1.10, 95% CI: 1.06 to 1.14), younger age (OR: 0.96, 95% CI: 0.95 to 0.97), lower blood pressure (OR: 0.96, 95% CI: 0.96 to 0.97), and having no history of renal insufficiency (OR: 0.91, 95% CI: 0.85 to 0.97). Use of digoxin in patients with HFpEF (n = 138,140) without AF was 9.8% in 2005, which decreased to 2.2% in 2014 (p_trend < 0.0001).

Conclusions

One in 5 HFrEF patients received digoxin at discharge, with a significant downward temporal trend in use over the study period. Use of digoxin in HFpEF patients without AF was very low and decreased over the study period.